This study is for patients who are HER2 (+) and have undergone surgery to remove the cancer and have residual disease. This study looks at adding Tucatinib to standard of care treatment.
Contact phone
Jessica Kong | (517) 364-2811
Contact email
[email protected]
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Breast
Webform